Table 1 Baseline characteristics of groups of patients with SARS-CoV-2 infection
Characteristics | Patients no. (%) | ||
|---|---|---|---|
Asymptomatic (n = 411) | Mild symptomatic (n = 551) | Severe symptomatic (n = 66) | |
Age | |||
< 20 | 60 (14.6) | 56 (10.2) | 0 (0,0) |
20–29 | 66 (16.1) | 90 (16.3) | 5 (7.6) |
30–39 | 73 (17.8) | 79 (14.3) | 2 (3.0) |
40–49 | 57 (13.9) | 92 (16.7) | 9 (13.6) |
50–59 | 92 (22.4) | 115 (20.9) | 16 (24.2) |
≥ 60 | 63 (15.3) | 119 (21,6) | 34 (51.5) |
Median (IQR) | 41 (26.0–54.0) | 46 (29.0–58.0) | 60 (50.5–71.5) |
Sex | |||
Male | 193 (47.0) | 251 (45.6) | 28 (42.4) |
Female | 218 (53.0) | 300 (54.4) | 38 (57.6) |
Skin colora | |||
White | 256 (62.3) | 347 (63.0) | 46 (69.7) |
Mestizo | 103 (25.1) | 125 (22.7) | 13 (19.7) |
Black | 51 (12.4) | 73 (13.2) | 7 (10.6) |
Comorbidity | |||
Hypertension | 108 (26.3) | 217 (39.4) | 40 (60.6) |
Asthma | 51 (12.4) | 93 (16.9) | 10 (15.2) |
Diabetes | 22 (5.4) | 61 (11.1) | 15 (22.7) |
Obesity | 22 (5.4) | 34 (6.2) | 6 (9.1) |
Cardiovascular disease (not including HT) | 18 (4.4) | 39 (7.1) | 13 (19.7) |
Hypercholesterolemia | 12 (2.9) | 19 (3.4) | 3 (4.5) |
Cancer | 7 (1.7) | 14 (2.5) | 3 (4.5) |
COPD | 6 (1.5) | 15 (2.7) | 6 (9.1) |
Bronchiectasis | 1 (0.2) | 3 (0.5) | 2 (3.0) |
Sleep apnea | 0 (0.0) | 1 (0.2) | 1 (1.5) |